Effect of Rosuvastatin Therapy on Biomarkers of Inflammation and Immune Activation in People With Human Immunodeficiency Virus at Intermediate Cardiovascular Risk
Published inThe journal of infectious diseases, vol. 224, no. 4, p. 667-672
Publication date2021-08-15
First online date2020-12-22
Abstract
Keywords
- HIV
- Cardiovascular disease
- Chronic inflammation
- Immune activation
- Monocytes
- Rosuvastatin
- Biomarkers / blood
- Cardiovascular Diseases / prevention & control
- HIV Infections / drug therapy
- Heart Disease Risk Factors
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
- Inflammation / drug therapy
- Monocytes
- Risk Factors
- Rosuvastatin Calcium / therapeutic use
Affiliation
Research group
Funding
- National Health and Medical Research Council (NHMRC) - A new monocyte atherogenic phenotype in chronic HIV disease. [1108792]
Citation (ISO format)
HEARPS, Anna C et al. Effect of Rosuvastatin Therapy on Biomarkers of Inflammation and Immune Activation in People With Human Immunodeficiency Virus at Intermediate Cardiovascular Risk. In: The journal of infectious diseases, 2021, vol. 224, n° 4, p. 667–672. doi: 10.1093/infdis/jiaa775
Main files (1)
Article (Published version)
Secondary files (1)
Identifiers
- PID : unige:161487
- DOI : 10.1093/infdis/jiaa775
- PMID : 34398237
ISSN of the journal0022-1899